vs
瑞思迈（RMD）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是SCANSOURCE, INC.的1.9倍（$1.4B vs $766.5M），瑞思迈净利率更高（27.6% vs 2.2%，领先25.4%），瑞思迈同比增速更快（11.0% vs 2.5%），瑞思迈自由现金流更多（$311.2M vs $28.9M），过去两年瑞思迈的营收复合增速更高（9.0% vs 0.9%）
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
RMD vs SCSC — 直观对比
营收规模更大
RMD
是对方的1.9倍
$766.5M
营收增速更快
RMD
高出8.4%
2.5%
净利率更高
RMD
高出25.4%
2.2%
自由现金流更多
RMD
多$282.3M
$28.9M
两年增速更快
RMD
近两年复合增速
0.9%
损益表 — Q2 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $766.5M |
| 净利润 | $392.6M | $16.5M |
| 毛利率 | 61.8% | 13.4% |
| 营业利润率 | 34.6% | 2.3% |
| 净利率 | 27.6% | 2.2% |
| 营收同比 | 11.0% | 2.5% |
| 净利润同比 | 13.9% | -3.3% |
| 每股收益（稀释后） | $2.68 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RMDSCSC
| Q4 25 | $1.4B | $766.5M | ||
| Q3 25 | $1.3B | $739.6M | ||
| Q2 25 | $1.3B | $812.9M | ||
| Q1 25 | $1.3B | $704.8M | ||
| Q4 24 | $1.3B | $747.5M | ||
| Q3 24 | $1.2B | $775.6M | ||
| Q2 24 | $1.2B | $746.1M | ||
| Q1 24 | $1.2B | $752.6M |
净利润RMDSCSC
| Q4 25 | $392.6M | $16.5M | ||
| Q3 25 | $348.5M | $19.9M | ||
| Q2 25 | $379.7M | $20.1M | ||
| Q1 25 | $365.0M | $17.4M | ||
| Q4 24 | $344.6M | $17.1M | ||
| Q3 24 | $311.4M | $17.0M | ||
| Q2 24 | $292.2M | $16.1M | ||
| Q1 24 | $300.5M | $12.8M |
毛利率RMDSCSC
| Q4 25 | 61.8% | 13.4% | ||
| Q3 25 | 61.5% | 14.5% | ||
| Q2 25 | 60.8% | 12.9% | ||
| Q1 25 | 59.3% | 14.2% | ||
| Q4 24 | 58.6% | 13.6% | ||
| Q3 24 | 58.6% | 13.1% | ||
| Q2 24 | 58.5% | 13.0% | ||
| Q1 24 | 57.9% | 12.6% |
营业利润率RMDSCSC
| Q4 25 | 34.6% | 2.3% | ||
| Q3 25 | 33.4% | 3.5% | ||
| Q2 25 | 33.7% | 3.3% | ||
| Q1 25 | 33.0% | 3.2% | ||
| Q4 24 | 32.5% | 2.5% | ||
| Q3 24 | 31.6% | 2.3% | ||
| Q2 24 | 31.2% | 2.9% | ||
| Q1 24 | 31.3% | 2.3% |
净利率RMDSCSC
| Q4 25 | 27.6% | 2.2% | ||
| Q3 25 | 26.1% | 2.7% | ||
| Q2 25 | 28.2% | 2.5% | ||
| Q1 25 | 28.3% | 2.5% | ||
| Q4 24 | 26.9% | 2.3% | ||
| Q3 24 | 25.4% | 2.2% | ||
| Q2 24 | 23.9% | 2.2% | ||
| Q1 24 | 25.1% | 1.7% |
每股收益（稀释后）RMDSCSC
| Q4 25 | $2.68 | $0.75 | ||
| Q3 25 | $2.37 | $0.89 | ||
| Q2 25 | $2.58 | $0.87 | ||
| Q1 25 | $2.48 | $0.74 | ||
| Q4 24 | $2.34 | $0.70 | ||
| Q3 24 | $2.11 | $0.69 | ||
| Q2 24 | $1.97 | $0.66 | ||
| Q1 24 | $2.04 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $83.5M |
| 总债务越低越好 | $403.9M | — |
| 股东权益账面价值 | $6.3B | $910.9M |
| 总资产 | $8.5B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.06× | — |
8季度趋势，按日历期对齐
现金及短期投资RMDSCSC
| Q4 25 | $1.4B | $83.5M | ||
| Q3 25 | $1.4B | $124.9M | ||
| Q2 25 | $1.2B | $126.2M | ||
| Q1 25 | $932.7M | $146.3M | ||
| Q4 24 | $521.9M | $110.5M | ||
| Q3 24 | $426.4M | $145.0M | ||
| Q2 24 | $238.4M | $185.5M | ||
| Q1 24 | $237.9M | $159.1M |
总债务RMDSCSC
| Q4 25 | $403.9M | — | ||
| Q3 25 | $408.7M | — | ||
| Q2 25 | $658.4M | — | ||
| Q1 25 | $663.1M | — | ||
| Q4 24 | $662.9M | — | ||
| Q3 24 | $667.6M | — | ||
| Q2 24 | $697.3M | — | ||
| Q1 24 | $997.0M | — |
股东权益RMDSCSC
| Q4 25 | $6.3B | $910.9M | ||
| Q3 25 | $6.1B | $914.0M | ||
| Q2 25 | $6.0B | $906.4M | ||
| Q1 25 | $5.5B | $901.7M | ||
| Q4 24 | $5.3B | $900.7M | ||
| Q3 24 | $5.2B | $920.9M | ||
| Q2 24 | $4.9B | $924.3M | ||
| Q1 24 | $4.6B | $944.1M |
总资产RMDSCSC
| Q4 25 | $8.5B | $1.7B | ||
| Q3 25 | $8.3B | $1.7B | ||
| Q2 25 | $8.2B | $1.8B | ||
| Q1 25 | $7.6B | $1.7B | ||
| Q4 24 | $7.1B | $1.7B | ||
| Q3 24 | $7.2B | $1.8B | ||
| Q2 24 | $6.9B | $1.8B | ||
| Q1 24 | $6.8B | $1.8B |
负债/权益比RMDSCSC
| Q4 25 | 0.06× | — | ||
| Q3 25 | 0.07× | — | ||
| Q2 25 | 0.11× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $339.7M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $311.2M | $28.9M |
| 自由现金流率自由现金流/营收 | 21.9% | 3.8% |
| 资本支出强度资本支出/营收 | 2.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.87× | 1.87× |
| 过去12个月自由现金流最近4个季度 | $1.8B | — |
8季度趋势，按日历期对齐
经营现金流RMDSCSC
| Q4 25 | $339.7M | $30.8M | ||
| Q3 25 | $457.3M | $23.2M | ||
| Q2 25 | $538.8M | — | ||
| Q1 25 | $578.7M | $66.1M | ||
| Q4 24 | $308.6M | $-6.2M | ||
| Q3 24 | $325.5M | $44.8M | ||
| Q2 24 | $440.1M | — | ||
| Q1 24 | $402.0M | $160.2M |
自由现金流RMDSCSC
| Q4 25 | $311.2M | $28.9M | ||
| Q3 25 | $414.4M | $20.8M | ||
| Q2 25 | $508.2M | — | ||
| Q1 25 | $557.9M | $64.6M | ||
| Q4 24 | $288.0M | $-8.2M | ||
| Q3 24 | $307.7M | $42.5M | ||
| Q2 24 | $415.2M | — | ||
| Q1 24 | $380.8M | $157.7M |
自由现金流率RMDSCSC
| Q4 25 | 21.9% | 3.8% | ||
| Q3 25 | 31.0% | 2.8% | ||
| Q2 25 | 37.7% | — | ||
| Q1 25 | 43.2% | 9.2% | ||
| Q4 24 | 22.5% | -1.1% | ||
| Q3 24 | 25.1% | 5.5% | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 31.8% | 21.0% |
资本支出强度RMDSCSC
| Q4 25 | 2.0% | 0.3% | ||
| Q3 25 | 3.2% | 0.3% | ||
| Q2 25 | 2.3% | 0.3% | ||
| Q1 25 | 1.6% | 0.2% | ||
| Q4 24 | 1.6% | 0.3% | ||
| Q3 24 | 1.5% | 0.3% | ||
| Q2 24 | 2.0% | 0.2% | ||
| Q1 24 | 1.8% | 0.3% |
现金转化率RMDSCSC
| Q4 25 | 0.87× | 1.87× | ||
| Q3 25 | 1.31× | 1.17× | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.59× | 3.79× | ||
| Q4 24 | 0.90× | -0.36× | ||
| Q3 24 | 1.05× | 2.64× | ||
| Q2 24 | 1.51× | — | ||
| Q1 24 | 1.34× | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
